Ra Pharms

RARX NASDAQ
29.24
+0.27
+0.93%
After Hours: 29.24 0 0.00% 16:36 08/20 EDT
Open
28.86
Prev Close
28.97
High
29.79
Low
28.86
Volume
537.03K
Avg Vol (3M)
513.00K
52 Week High
36.96
52 Week Low
10.02
% Turnover
1.14%
Market Cap
1.37B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Ra Pharms RARX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system. It is developing its lead product candidate, RA101495, a self-administered subcutaneous (SC) injection. RA101495 is injected into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The Company is also developing RA101495 to treat other debilitating complement-mediated diseases such as generalized myasthenia gravis (gMG) and lupus nephritis (LN). It also focuses on discovery and preclinical programs targeting selective inhibition of other uncontrolled complement pathway factors to treat a variety of ophthalmic, renal and inflammatory diseases. The Company uses its Extreme Diversity platform, macrocyclic peptide chemistry technology which produces synthetic macrocyclic peptides.
MORE >

Recently

Name
Price
%Change